A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.
Proneth
Bettina
B
Department of Medicinal Chemistry, University of Florida, Gainesville, FL 32610, USA.
Portillo
Federico P
FP
Haskell-Luevano
Carrie
C
D008024:Ligands; D016297:Mutagenesis, Site-Directed; D044104:Receptor, Melanocortin, Type 3 / Q000819:agonists* / Q000737:chemistry / Q000235:genetics; D013329:Structure-Activity Relationship
D008024:Ligands; D044104:Receptor, Melanocortin, Type 3